Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
Background. In the Russian Federation, in 2018 3,207 new cases of Hodgkin’s lymphoma (HL) were detected, mainly in adults. Despite significant advances in the treatment of this disease, approximately 20–30 % of patients develop relapses. High-dose chemotherapy with autologous hematopoietic stem cell...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2020-12-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/449 |